In previous work, the direct injection of 50 /Mg of a plasmid DNA vector encoding firefly luciferase (VR1205) into murine quadriceps muscle produced an average of 6.5 ng of luciferase per muscle at 7 days postinjection. In this report, various elements of the VR1205 vector were modified to increase gene expression levels or to eliminate undesired viral sequences. Expression of the modified vectors was then compared to VR1205 using the intramuscular injection assay. In general, modifications to promoter, enhancer, and intronic sequences either decreased luciferase expression levels or had no effect. However, modifications to the polyadenylation and transcriptional termination sequences, plasmid backbone elements, and the luciferase gene itself each increased luciferase expression levels. The best-expressing vector, designated VR1255, contained a combination of these incrementally beneficial changes. A single intramuscular injection of 50 /ug of VR1255 produced 300 ng of luciferase at 7 days postinjection, an expression level 46-fold higher than the VR1205 vector (or 22-fold higher, excluding modifications to the luciferase gene) and 154-fold higher than a commercially available luciferase expression vector. Thus, VR1255 represents an improved plasmid DNA vector that may be useful for gene therapy applications.
INTRODUCTION
VARIOUS VIRAL DNA DELIVERY VEHICLES, SUCh aS rCttOvfral and adenoviral vectors, have been employed experimentally to ttansduct skeletal muscle . Rettovkal vectors eUcit low ttansgene expression in undamaged muscle, whereas adenovkal vectors generate relatively high ttansduction levels. However, accessory proteins carried or produced by current adenoviral vectors elicit a sttong local inflammatory response as well as systemic humoral and cellular immune responses. Such responses may contribute to the fransient expression observed with adenoviral vectors and may render the muscle refractory to repeat ttansductions Yang et al, 1994) .
Plasmid DNA-based gene deUvery vehicles, unlike vfral ones, do not requke foreign accessory proteins for deUvery of DNA into cells. The injection of plasmid DNA encoding heterologous genes into mouse skeletal muscle results in the production of the encoded gene product in mature myofiber cells (Wolff et al, 1990) . Plasmid DNA-based skeletal muscle ttansfection has been demonstrated across various vertebrate species using various reporter genes and plasmid vectors (Wolff et al, 1990; Hansen et al, 1991; Jiao et al, 1992; Cox et al, 1993; Mantiiorpe et al, 1993; Xiong et al, 1995; Liang et al, 1996) . Experimentally, DNA-based inttamuscular ttansfection is an effective approach for immunization against infectious vkal, mycoplasmic, protozoan, and platyhelnuntiiian pathogens (Ulmer Departments of 'Cell Biology, •^Molecular Biology, and ^Pharmaceutical Development, Vical Incorporated, San Diego, CA 92121. ''Both authors made equally significant contributions to this work. Sedegah et al, 1994; Barry et al, 1995; Xu and Liew, 1995; Yang et al, 1995) , for immunization against the onset of cancer (Conry et al, 1995; Spooner et al, 1995) , to correct myogenetic diseases (Acsadi et al, 1991) , and to deliver therapeutic proteins into the systemic circulation (Fazio et al, 1994; Ma et al, 1995) . In addition, plasmid DNA injections resuh in fransgene expression in other tissues besides skeletal muscle (Lin et al, 1990; Tomita et al, 1992; Davis and Jasmin 1993; Raz era/., 1993; Sahenk era/., 1993; Hickman et al, 1994) .
Here, mouse skeletal muscle was used as an in vivo assay platform to quantify expression levels from a series of modified plasmid DNA vectors. In an experimental effort to increase reporter gene expression, modifications were made to various eukaryotic gene regulatory elements, including promoters, enhancers, infrons, and transcriptional termination signals. In addition, prokaryotic antibiotic resistance genes and backbone elements were altered and undesired vkal sequences were removed to produce a plasmid more acceptable for cUnical use. Finally, a modified luciferase gene with optimized codon usage and a mutated peroxisomal targeting sequence was employed to enable higher expression of this infracellular reporter protein. The most potent newly engineered vectors elicited markedly higher expression levels than previously available vectors. Plasmid DNA construction Details regarding constraction ofthe plasmids utiUzed in this study are shown in Table 1 . Plasmid VCLIOIO was derived from p-CMVint-Bl (Mantiiorpe et al, 1993) by digesting pCMVint-Bl with Nar I, filUng in tiie ends witii the Klenow fragment of DNA polymerase I, and partially digesting the resulting fragment with Alw NI to remove the ampicilUn-resistance gene. The kanamycin-resistance gene fragment was isolated from pET9a (Novagen, Madison, WI) by digesting with Eco RI, filling in the overhangs with the Klenow fragment of DNA polymerase I, and digesting the resulting fragment with Alw NI. The kanamycin-resistance gene fragment was then Ugated into the vector fragment of p-CMVint-Bl to make the intermediate plasmid nkCMVintBl. nkCMVintBl was modified exactly as described for VRI206 (replacement of SV40 terminator with BGH terminator; Table 1 ) and VRI207 (removal of SV40 origin; Table 1) , and a synthetic double-sfranded polyUnker fragment (5'-CACGTGTGAT CAGATATCGC GGCCGCTGTA GACCAGGCGC CTG-3' witii matching 5' 5a/1 and 3' Bam HI overhangs) was inserted between the Sal I and Bam HI sites to make VCLIOIO.
MATERIALS AND METHODS

Reagents
Plasmid VR1012 was derived from VU-neo by digestmg VIIneo with Pst I and Bgl II, and subcloning a synthetic doublestranded polyUnker fragment 5'-TCACCGTCGT CGACACGTGT GATCAGATAT CGCGGCCGCT CTAGACCAGG CGCCTG-GATC C-3' witil matching 5' Pjf I and 3' Bgl n overhangs into the VU-neo vector fragment. The synthetic double-sfranded oligonucleotides used in constmcting VR1253 and VR1255 were 5'-GTCCTTTCCT AATAAAATGA GGAAATTGCA TCG-CATTGTC TGAGTAGGTG TCATTCTATT CTGGGGGGTG GGGTGG-3' (VR1253) and 5'-ACTTCTGGCT AATAAAAGAT CAGAGCTCTA GAGATCTGTG TGTTGGTTTT TTGTGT-3' (VR1255), with 5' Bgl U and 3' Kpn 1 overhangs added to facilitate subcloning. The VU-neo plasmid was provided by I. Shiver (Merck, Sharp and Dohme Research Laboratories, Westpoint, PA) and was identical to VU (Montgomery et al, 1993) except tiiat the ampicillin-resistance gene was replaced with the neomycin/kanamycin-resistance gene derived from plasmid puc4K (Pharmacia, Piscataway, Nl). Plasmid pGL3Luc-l-(pGL3-Confrol Vector) was obtained from Promega (Madison, WI; Cat. No. E1741). Plasmids pRSVL (de Wet et al, 1987) and pRSVL-c (pSG244; Gould et al, 1989) were generous gifts of Suresh Subramani. Sources for all other plasmids are listed in the legend for Table 1 .
Plasmid DNA purification Plasmid DNA was fransformed into Escherichia coli DH5a-or DHIOB-competent cells and grown m Terrific Broth (Sambrook et al, 1989) complemented with 100 /Ag/ml ampicillin or 50 /tg/ml kanamycin in a 5-liter fermentor (Applikon, Foster City, CA). Temperature and pH were confrolled at 30° ± 0.5°C and 7.0 ± 0.5, respectively. The stkring speed was set at 600 ± 50 rpm and the ak flow was set at 1 liter/liter/min. Cells were harvested by centrifiigation at the end of the exponential growth phase (approximately 10 hr), typically yielding 400 grams of biomass net weight. Covalently closed ckcular plasmid DNA was isolated by a modified lysis procedure (Hom et al, 1995) followed by standard double CsCl-ethidium bromide gradient ulfracentrifugation, with an average yield of approximately 25 mg. Endotoxin content was determined by the Limulus Amebocyte Lysate (LAL, Associates of Cape Cod, MA) assay. Protein content was determLned using the bicinchoninic acid assay (Pierce Chem. Co., Rockford, EL). All plasmid preparations were free of detectable chromosomal DNA, RNA, and protein impurities based on gel anailysis and the bicinchoninic assay. Endotoxin levels were less than 0.6 Endotoxin Units//i,g of plasmid DNA. The specfrophotometric A260M280 ratios were between 1.75 and 2.0. Plasmids were ethanol precipitated and resolubilized Ul USP salme at 4°C. DNA was stored at -20°C.
Intramuscular injection of plasmid DNA
The quadriceps muscle of resfrained, awake mice was injected percutaneously with 50 fil of DNA in saline using a disposable sterile, plastic insulin syringe and 28G one-half needle (Becton-Dickenson, Rutherford, NJ, Cat. No. BD9430) fitted with a plastic collar cut from a micropipette tip. The collar length was adjusted to limit the needle-tip penefration to a distance of about 2 mm into the centtal part of the rectus femoris muscle. Injection fluids and syringes were equilibrated to room temperature, and the injection of a single 50-fil volume was carried out in 1-2 sec. Animal care throughout the study was in compliance with the "Guide for the Use and Care of Laboratory Animals" (U.S. Department of Health and Human Services, National Institutes of Health, NIH Publication No. 86-23, revised 1985) as well as with Vical's Institutional Animal Care and Use Committee.
Extraction of luciferase from mouse muscle Animals were euthanized at various times postinjection with an overdose of sodium pentobarbital (Euthanasia-5; 4.5 mg/mouse i.p.), and the entke quadriceps muscle group (150-200 mg wet weight) was collected from each mouse leg and immediately frozen on dry ice in 1.5-ml Eppendorf tubes. Tissue samples were stored at -78°C until processing. Frozen muscles were ttansferred into 2.0-ml microcentrifuge tubes containing 0.4 ral of frozen lysis buffer (Promega Cell Culture Lysis Reagent), and the tubes were inserted into a metal heat block partially immersed in a liquid nitrogen bath. The frozen muscles were then ground into a fme powder using a reversible electric masonry drill (SKIL Xtta-tool 600, SKIL Corp., Chicago, IL) with a 19/64" bit. The bit was driven in the reverse dkection to prevent the powder from rising through the bit grooves, and brashed clean between samples to prevent cross-contamkiation. Approximately 30-50 muscles could be pulverized into powder in 1 hr using the drilling procedure. Samples not exttacted immediately after grinding were stored frozen at -78°C ovemight without loss of luciferase activity. Frozen muscle powders were thawed by adding 0.1 ml of lysis buffer. The samples were vortexed at room temperamre for 15 min using a multitube platform, frozen, and thawed three times uskig altematmg liquid nittogen and 23°C water baths, and centrifuged 3 min at 10,000 X g. The supematant was ttansferred to a separate 1.5-ml mbe kept at 4°C, another 0.5 ml lysis buffer was added to the pellet, and the exttaction process was repeated without freeze-thawing. The second supematant was combined with the fkst, and the exttact was stored at -78°C until assay. Uninjected conttol muscle exttacts were prepared in the same manner and used in luciferase standard curve assays as described previously (Manthorpe et al, 1993) .
Luciferase enzyme assays
Luciferase activity was assayed using an microplate luminometer (Dynatech, Chantilly, VA, model ML2250). One hundred microliters of luciferase substtate was automatically added to 20 pX of muscle exttact and sample Light Units were recorded several times within 5 sec after addition. The luciferase content of tiie samples was calculated from Relative Light Units using a standard curve of purified firefly luciferase, which was diluted in pooled exttact from uninjected muscles to control for quenching. The specific activity of the commercial fkefly luciferase enzyme reagent was reported by the manufacturer to be 1.69 X 10'^ Relative Light Units/mg protein (Analytical Luminescence Labs, Cat. No. 2400) . Luciferase values were expressed as nanograms of luciferase per milliliter of muscle exfract. The luciferase assay yielded <5% variation in Light Units within triplicate samples. In conttol experiments, representative muscle exttacts containing high, medium, and low levels of luciferase activity were stored at -78°C in replicate aliquots and periodically assayed over a 3-year interval, yielding < 10% variation in Light Units.
Statistical evaluations
All statistical comparisons were performed using the nonparametric Mann-Whitney rank sum test (SigmaStat version 1.1, Jandel Scientific Software, San Rafael, CA). This rank-order test was chosen because it makes no assumptions regarding the type of distribution of values around the mean {e.g., normal, log-normal, etc.), and is valid for use in comparing two mdependent groups that contain the same or different numbers of values. Experimental group averages were considered significantly different from confrol group averages if the p value was less than 0.05.
RESULTS
To detennine a single DNA dose and postinjection time point to use for vector comparisons, we analyzed the inframuscular dose-response and time course of luciferase expression from the VR1205 plasmid. Because VR1205 represented a standard vector for comparison with newly engineered luciferase vectors, it was assayed repeatedly in dose-response and time-course analyses. The data from all of tiie VR1205 assays were averaged and are presented in Fig. 1 . As shown in Fig. IA , VRI205 expression at 7 days after injection ranged from 0.1 ng of luciferase when 1 /lg of DNA was injected, to about 6-9 ng of luciferase when 50-250 /tg of DNA was mjected. Expression levels decUned to about 4 ng of luciferase when the DNA dose reached 500 /tg. Peak expression 7 days after a 50-/tg DNA dose was 6.5 ± 0.3 ng luciferase/muscle (average ± SEM, n = 851 muscles). This level is similar to tiie 6.2 ± 0.6 ng/muscle level previously reported using fewer muscles (Manthorpe et al, 1993 ; average ± SEM, n = 210 muscles). Figure IB shows the average levels of expression up to 1 year after a single injection of 50 /tg of VRI205 DNA. Inttamuscular expression averaged about 2 ng of luciferase/ muscle at 1 day, and then rose to a maximum level of about 6 ng luciferase/muscle at 7-14 days. Thereafter, expression decUned to reach a stable level of about 0.3 ng of luciferase by 21 days. This lower level of expression persisted in muscle for at least 1 year (the longest time point examined). On the basis of the results shown in Fig. 1 , the 50-/tg DNA dose and 7-day time point were chosen as conditions for the comparison of inttamuscular luciferase expression among the modified plasmid vectors.
To test whetiier luciferase expression was different in another inbred mouse sfrain, two batches of VRI 205 were tested by dose-response and time-course analyses in C57BL/6 mouse rectus femoris muscle. As in BALB/c mice, expression peaked around days 7-14 and the maximum expression level in C57BL/6 mouse muscle was obtained with 50-100 /tg of DNA (data not shown). The average expression level in C57BL/6 mouse muscle deriving from the 50-/tg DNA dose at day 7 was 7.6 ± 1.2 ng luciferase/muscle (average ± SEM, n = 50 muscles), indicating that luciferase expression was not appreciably different from that in BALB/c muscle.
To evaluate the effects of various gene regulatory elements and plasmid backbone sequences on inframuscular luciferase expression, the VRI 205 vector, or preexisting luciferase plasmids derived from nRSVLux (Manthorpe et al, 1993) , were modified as shown in Table 1 . The general stractures of the parental and modified plasmids are presented in Fig. 2 . Luciferase expression levels for each plasmid were determined in sets of eight to ten muscles per experiment, and at least four experiments were performed per plasmid. The average nanograms of luciferase per muscle values are shown in Fig. 3 and Table 2 . Average expression levels are also shown for the confrol plasmids pGL3Luc-I-, pRSVL and pRSVL-c (shaded bars in Fig. 3A ). A. BALB/c mouse rectus femoris muscles were injected with the indicated amount of DNA in 50 /tl of saline. The muscles were collected, exfracted, and the exfracts were assayed for luciferase enzyme activity at 7 days post-injection. Six different fermentation batches of VRI205 were each tested at least twice. At least eight muscles were injected for each dose in each experiment, although the 500 /tg of the DNA dose was not assayed in all the experiments. The solid thick line represents the overall average ± SEM of all the experiments. The total number of muscles assayed for each DNA dose was: 127 (1 /tg), 115 (5 /tg), 130 (10 /tg), 120 (25 /tg), 130 (50 /ig), 128 (100 /tg), 126 (250 /tg), and 50 (500 /tg). B. The same six batches of VRI 205 were tested in BALB/c mice by time-course analyses. Muscles were injected with 50 /tg of plasmid DNA and luciferase activity was analyzed at the indicated time points post-injection. The soUd thick line represents the overaU average expression ± SEM. The total number of muscles assayed for the indicated day time point was: 140 (1 day), 156 (7 days 
Promoter/enhancers
The human cytomegalovkus (CMV) immediate early I gene promoter/enhancer, a very sfrong vkal promoter/enhancer (Thomsen et al, 1984; Boshart ef al, 1985; Ghazal et al, 1987) was subcloned in place of tiie Rous sarcoma vkus (RSV) promoter/enhancer kl nRSVLux to produce tiie plasmid VRI204. As shown in Fig. 3 A and Table 2 , inttamuscular injections of VR 1204 jdelded over two-fold higher luciferase expression values relative to nRSVLirx (5.2 v.y. 2.2 ng/muscle). The promoter/enhancer of the murine oB crystalUne gene (cryB) has been demonsfrated to effect high-level inframuscular reporter expression in fransgenic mice (Dubin et al, 1991) . However, replacement of tiie RSV promoter/enhancer of nRSVLux with that of cryB to produce cryBLux resulted in a decrease in luciferase expression (1.3 vs. 2.2 ng/muscle; Fig. 3A and Table 2 ). The CMV promoter/enhancer was therefore utiUzed for all subsequent vector modifications.
Introns
Inttons have been shown to increase gene expression from plasmids and in fransgeiuc mice (Huang and Gorman, 1990b; Chapman et al, 1991; Choi et al, 1991 *A total of 50 /tg of plasmid DNA was injected into mouse muscle and luciferase activity was measured at 7 days postinjection. In each experiment, eight to ten muscles were injected per plasmid, and each constract was tested in 4-90 separate experiments.
• Average values for all other vectors were significantly different from one another at level p < 0.001.
the CMV immediate early gene, intton A, has been shown to increase expression of heterologous genes from plasmids in vitro (Chapman et al, 1991) . Therefore, the luciferase cDNA was subcloned into the plasmid p-CMVint-Bl downstteam of the CMV promoter/enhancer and 5' unttanslated sequences (including intton A) to make VR1205. VR1205 exhibited a modest but significant increase in luciferase expression relative to VR1204 (6.5 vs. 5.2 ng/muscle; Fig. 3A and Table 2 ).
Enhancers
To determine if exogenous enhancers could further increase the rate of luciferase gene ttanscription from the CMV promoter/enhancer, the cryB enhancer was subcloned upstteam of the CMV enhancer of VRI205 to produce the plasmid CMVcryBLux. In addition, the murine muscle creatine kinase (mck) enhancer, reported to effect prolonged high-level expression in vivo foUowing injection of mice with rettovirally transduced myoblasts (Dai etal, 1992) , was subcloned into the same region of VRI205 to produce the plasmid CMVmckLux. Insertion of the cryB enhancer increased intramuscular luciferase levels (8.5 vs. 6.5 ng/muscle), whereas insertion of the mck enhancer decreased luciferase expression (3.9 vs. 6.5 ng/muscle; Fig. 3A and Table 2 ).
Removal of SV40 sequences
To satisfy concems related to its potential clinical use, the VRI205 vector was modified to remove all SV40-derived sequences. These included the SV40 ttanscriptional tenninator (replaced in VR1205 to make plasnud VR1206), and tiie T-antigen-dependent vkal origin of replication, located immediately upstteam of the CMV promoter/enhancer (deleted from VR1206 to make plasmid VR1207). VR1206 exhibited a tiireefold increase in luciferase expression relative to VRI205 (see the Transcriptional terminators section, below) whereas VR1207 did not differ significantly from VR1206 (22.4 vs. 19.3 ng/muscle; Fig. 3B and Table 2 ).
Plasmid backbone elements
To eliminate the possibiUty of ttace amounts of ampicilUn (/.«., potentially present as a plasmid DNA contaminant) inducing anaphylactic shock in sensitized individuals, the ampicillin-resistance gene of VRI207 was replaced with tiie kanamycin-resistance gene to make plasmid VR1210. Unexpectedly, luciferase expression from VRI210 increased over two-fold compared to VR1207 (53.0 vs. 22.4 ng/muscle; Fig. 3B and Table 2 ). To enhance plasmid yields (Montgomery et al, 1993) , a modified pUC backbone was employed to constract plasmid VRI216 (Table 1 ; see also Materials and Methods). Relative to VR1210, the VR1216 backbone contained additional sequence elements from the 5' and 3' regions of the kanamycin-resistance gene, the orientation of the kanamycin-resistance gene was reversed, and residual ttanscriptional conttol and /3-galactosidase (;8-Gal) a-complementation elements from the Escherichia coli lacZ gene (located 5' to the CMV promoter/enhancer and 3' to the BGH tenninator) were removed. Together, these backbone changes increased luciferase expression another 1.5-fold (81.7 v*. 53.0 ng/muscle; Fig. 3B and Table 2 ).
Transcriptional terminators
The SV40 ttanscriptional terminator sequences of VR1205 were replaced with those of bovine growth hormone (BGH; Goodwin and Rottman, 1992) to make plasmid VRI206. Relative to tiie SV40 terminator, tiie BGH terminator region of VR1206 contributed much less 3' unttanslated region (3' UTR) sequence to the resulting luciferase mRNA {i.e., 117 v.y. ~ 800 bases), and also lacked the smaU t intton present in the SV40 terminator-derived 3' UTR sequences (Fiers et al, 1978) . These changes collectively resulted in a three-fold increase in muscle luciferase levels kl VR1206 relative to VR1205 (19.3 vs. 6 .5 ng/muscle; Fig.  3B and Table 2 ). To investigate furtiier tiie effects of 3' UTR and ttanscriptional termination sequences on luciferase expression, VRI223, which contained a modified luciferase gene (see the Luciferase coding sequences section, below) was utiUzed as the parental plasmid. The BGH ttanscriptional terminator of VR1223, identical to that of VR1206, was replaced with a minimal ttanscriptional terminator derived from the rabbit ;8-globin gene (Levitt et al, 1989) containing the essential polyadenylation signal and downsfream tennination elements, but lacking any upsfream 3' UTR sequence. The presence of this optimized ttanscriptional terminator in VR1255 further increased luciferase expression by nearly two-fold in comparison to VRI 223 (301 vs. 175 ng/muscle; Fig. 3B and Table 2 ). In a related experiment, a VR1223-derived plasmid containing a minimal version of the BGH terminator lacking any upstteam 3' UTR sequence (VRI253) produced no significant change in luciferase expression (185 vs. 175 ng/muscle; Table 2 ).
Luciferase coding sequences
In the course of the above experiments, the Photinus pyralis luciferase cDNA subcloned in VRI 216 and all preexisting luciferase plasmids were replaced with the modified Luc-I-gene (Promega, Madison, Wis.). Relative to the P. pyralis luciferase cDNA, the Luc-I-gene differed in the following respects: (i) the carboxy-tenninal peroxisomal targeting sequence Ser-LysLeu was changed to Ile-Ala-Val, resulting in the targeting of luciferase to the cytoplasm; (ii) insect codon usage was altered to reflect mammalian codon preferences; (iii) potential transcription factor binding sites within the luciferase cDNA were ablated; (iv) the amino acid sequences of two potential AT-Unked glycosylation sites were altered, Asnso -» Aspso and Asn 119 -> Gly 119; (v) extended paUndromic DNA sequences were disrapted; and (vi) remnant wild-type luciferase 5' and 3' UTR sequences were removed. The resultant plasmid, VR1223, demonsfrated a 2.1-fold increase in luciferase expression relative to VR1216 (175 vs. 81.7 ng/muscle; Fig. 3B and Table 2 ). In related experiments, direct injection of the plasmid pRSVLc (pSG244; Gould et al, 1989) in which the native P. pyralis luciferase carboxyl terminus was mutated from Ser-Lys-Leu to Ser-Lys-Val to abolish its peroxisomal targeting activity, produced a 2.7-fold greater level of luciferase relative to the parental plasmid pRSVL (6.1 vs. 2.3 ng/muscle; Fig. 3A and Table 2 ). Because the only difference between pRSVL and pRSVL-c is the mutation ofthe peroxisomal targeting sequence, these data suggest that the gain in expression reaUzed by insertion of the Luc-I-gene into VRI223 results primarily from the targeting of the Luc-I-gene product to the cytoplasm.
Range and distribution of luciferase expression
Other comparative aspects of the inframuscular expression of luciferase by these plasmids are noteworthy, and are presented in Table 2 . The highest individual expression values for the top three vectors (VR1223, VR1253, and VR1255) were all greater tiian 1 /tg of luciferase per muscle. The median values for these vectors consistently exceeded 100 ng/muscle, and represented 60-85% of the average (mean) values. Percentage distribution graphs of the expression data for selected vectors are shown in Fig. 4 . VirtuaUy aU (>98%) of the expression values from VR1205 injections yielded less than 32 ng/muscle. In confrast, only 10% of the expression values from VR1255 injections yielded less than 32 ng/muscle. Also, injection of VR1255 DNA resulted in half of the muscles expressing over 250 ng of luciferase, while injection of VR1205 yielded no muscles expressing in this range.
Dose-response analyses
The differences in average expression values between the plasmids shown in Fig. 3 and Table 2 were detennined using a single 50-/tg DNA injection and tiie 7-day postinjection time point. To determine if vector modifications might have altered dose-response and time-course expression profiles, selected plasmids were chosen for more detailed analyses. For the dose-response experiments, 10 quadriceps muscles were injected with each DNA dose, and at least two separate experiments were conducted for each plasmid. The results are shown in Fig. 5A . All the plasmids tested elicited very similar dose-dependencies of expression. Luciferase expression rose with doses from 1 to 50 /tg DNA, then reached a plateau that was maintained to 250 /tg of DNA. Some plasmids exhibited lower or higher plateau values, compared to the average dose-response plateau value of the VRI205 plasmid (thick line in Fig. 5A ). Dkect intramuscular injection of the commercially available pGL3Luc-l-plasmid, which expressed the LUC-I-gene product under the control of SV40 promoter, enhancer, and tenninator elements, elicited an average plateau value of about 2 ng of luciferase per muscle (Fig. 5A) . The most potent vector, VRI255, produced a 150-fold higher average plateau value of about 300 ng of luciferase per muscle. In fact, injection of only 1 /tg of VR1255 DNA elicited an average of over 4 ng of luciferase per muscle, which is comparable to that eUcited by 50 /tg of pGL3Luc-l-or VR1205.
Time-course analyses
The time course of inframuscular expression from representative plasmids is shown in Fig. 5B . All plasmids tested ex-28 r , VR1205
hibited a temporal pattem of luciferase expression that was similar to that for VR1205 (thick Une in Fig. 5B ). That is, all plasmids eUcited detectable luciferase expression at 1 day postinjection, which rose to a peak at 7-14 days, declined thereafter, and persisted at a stable low level. Regardless of the peak expression values (ranging from about 2.0 to almost 60 ng/muscle), luciferase expression from all plasmids decUned to about 0.3 ng/muscle by 60 days postinjection. This low level of expression persisted for at least 365 days, reflecting the presence of minimal levels of luciferase {i.e., >l-5 pg/muscle) in all muscles examined. While different plasmids assayed at 7-14 days post DNA injection revealed over 30-fold variation in thek peak expression values, no differences were observed in expression kinetics. Therefore, tiie various vector modifications analyzed did not alter tiie dose-response or time course of luciferase expression.
DISCUSSION
Direct inframuscular injection of an RSV promoter-driven luciferase plasnud DNA (pRSVL) was initially reported to yield 0.18 ng of luciferase per muscle at 7 days postinjection (Wolff et al, 1990) . The dkect inframuscular injection assay was used in subsequent experiments to develop an improved VRI205 plasmid vector (then termed "p-CMVint-lux"), which expressed 6.5 ng of luciferase per muscle (Manthorpe et al, 1993) . Further improvements in vector potency have been achieved in the present work, where we report tiiat the VRI 255 vector expresses an average of 301 ng of luciferase per muscle (Fig. 3B) . A commercially available vector, pGL3Luc-l-, was also tested and found to yield 2.0 ng of luciferase per muscle (Fig. 3A) . Thus, the VR1255 vector produces 1,672-150-, or 46-fold more fransgene product than the previous pRSVL, pGL3Luc-l-, and VR1205 plasmid vectors, respectively. Even excluding the 2.1-fold improvement reaUzed by replacement of the Lux gene with the Luc-I-gene, a change most applicable to the peroxisometargeted luciferase reporter used here, the VRI255 vector still gave a 22-fold increase in muscle expression over the parent VRI205 vector. The above improvements in expression were the cumulative result of changes to eukaryotic gene regulatory elements as well as to prokaryotic vector backbone sequences in VRI205. The promoter/enhancer of the VR1255 plasmid, derived from the CMV immediate early 1 gene (Thomsen et al, 1984) , was unchanged from that of VRI205. Addition of the mck enhancer, reported to prolong expression from the CMV promoter/enhancer (Dai et al, 1992) Table 2 were assigned to bins tiiat feU within the ranges of < 1, 1-2,2-4,4-8,8-16,16-32,32-64,64-125,125-250,250 -500, 500-1,000, or > 1,000 ng of luciferase/muscle. sion from VRI205. The mck enhancer also failed to effect longterm expression of luciferase, declining from a peak expression value of 3.9 ± 0.4 ng/muscle (average ± SEM, n = 160) at 7 days to 0.6 ± 0.2 ng/muscle (n = 20) at 28 days, and remaining low thereafter. This result may reflect immunologic mechanisms independent of gene franscription (see below). Interestingly, addition of the cryB enhancer to VRI205 produced a small but statistically significant increase in luciferase expression, demonsfrating that the ttanscriptional activity of the CMV promoter/enhancer can be further stimulated by the presence of upstteam enhancer elements. Experiments to identify more potent enhancer elements and optimize their positioning with respect to the CMV promoter are in progress.
The CMV intton A has been demonsttated to improve expression of heterologous genes expressed in vitro with the CMV immediate early I or other promoter/enhancers (Chapman et al, 1991) . The beneficial effect of inttons on expression has been ascribed primarily to an enhanced rate of RNA polyadenylation and/or nuclear ttansport associated with RNA spUcing (Huang and Gorman, 1990b) , but may also reflect the presence of ttanscriptional enhancers within the intton (Chapman et al, 1991) . For example, the CMV intton A contains multiple regions of homology to the muscle regulatory element of the quail ttoponin I gene, and the CMV promoter/enhancer with intton A has been reported to confer high-level muscle-specific expression in ttansgenic mice (Mikkelsen et al, 1992) . However, as shown in Fig. 3A (VR1204 vs. VR1205 ), the addition of the CMV intton A led to only a slight increase in luciferase expression (5.17-6.50 ng luciferase/muscle; p < 0.05; Table 2 ), suggesting its effects on plasnud gene expression are minimal in the context of dkect injection of plasmid DNA into skeletal muscle. Altematively, the effect of the CMV intton A on luciferase expression from VRI205 may be masked by the inhibitory effect of the SV40 small t intton present in the SV40 terminator 3' UTR sequences (Evans and ScarpuUa, 1989 ; see also discussion below).
A more than three-fold increase in luciferase expression was reaUzed by a series of alterations to prokaryotic plasmid backbone elements (VR1207 vs. VR1210; VR1210 vs. VR1216; Fig.   FIG. 5 . Dose-responses and time courses of luciferase expression from different plasmid DNA vectors. A. Fourteen different luciferase expression vectors were studied using dose-response analyses. In each experiment, the indicated amount of plasnud DNA in 50 /tl of saline was injected into rectus femoris muscles of BALB/c mice. Muscles were collected and exfracted, and the exfracts were assayed for luciferase enzyme activity at 7 days post-injection. Each plasmid constract was tested at least in two separate experiments and the average expression level for each constract is shown {n = 20-120 muscles per DNA dose per vector). B. The time course of expression for seven different constracts was determined by injecting 50 /tg of plasnud DNA into rectus femoris and analyzing the muscles at the indicated time points postinjection. Each constinct was tested at least twice, and the average expression level for each constract is shown {n = 20-170 muscles per time point per vector). For comparison, the VR1205 plots from Fig. 1 are shown (solid thick Une). 3B). The mechanism of this increase remains obscure. It may reflect the removal of cryptic eukaryotic ttanscriptional repressors or, conversely, the insertion of cryptic ttanscriptional enhancers. Such plasmid backbone modifications could also have caused alterations to the physical stracture of the DNA itself, thereby faciUtating the recraitment of ttanscription factors at distal promoter/enhancer sites (Perez-Martin et al, 1994) . These and other possibiUties are currentiy under investigation.
Transcriptional terminators are not widely recognized as gene regulatory elements. However, the efficiency of primary RNA ttanscript processing and polyadenylation is known to vary between ttanscriptional terminators of different genes. Moreover, as the rate of ttanscriptional initiation is increased by the use of sttong promoter/enhancers, the process of ttanscriptional termination may become rate-Umiting (Proudfoot and Whitelaw, 1988; Proudfoot, 1989) . In the experiments reported here, multiple modifications to ttanscriptional terminator sequences led to increases in inttamuscular luciferase expression. In the first of these modifications, replacement of the SV40 early region terminator with sequences derived from the BGH gene resulted in a threefold elevation in luciferase expression (VR1205 v.y. VR1206; Fig. 3B ). This increase may, in part, reflect differences in franscriptional termination efficiency, because the BGH terminator contains novel sequence elements downsfream of the polyadenylation site that are required for its activity and are distinct from conesponding downstteam elements present in the SV40 terminator (Goodwin and Rottman, 1992) . However, other factors may also account for the increased luciferase expression observed with VRI206. For example, the 3' UTR of the predicted luciferase mRNA of VRI205 (derived from the SV40 terminator sequences) is over six times longer than tiiat of VRI206. In addition, this region of the primary luciferase transcript of VRI205 includes the SV40 small t intton, reported to inhibit gene expression due to aberrant splicing with cryptic splice donors present in upstteam coding sequences (Evans and ScarpuUa, 1989; Huang and Gorman, 1990a) . These differences between the SV40 and BGH 3' UTR-derived sequences raise the possibility that either mRNA-destabilizing elements in the SV40 3' UTR, or abenant splicing of the SV40 t intton, may hamper luciferase expression from constracts containing the SV40 early region terminator.
The rabbit ;8-globin ttanscriptional terminator of VR1255 contains both GU-rich and U-rich sequence elements shown previously to be requked for mRNA 3' end formation (Gil and Proudfoot, 1987) . In general, these sequences are poorly conserved between genes, but appear to be critical for efficient mRNA cleavage prior to poly (A) tail addition (Bimstiel et al, 1985; McLauchlan era/., 1985; Proudfoot, 1991) . Interestingly, both the GU-and U-rich elements appear to be absent in the BGH terminator, where thek function may be supplanted by other novel sequence elements (Goodwin and Rottman, 1992) . As shown in Fig. 3B , replacement of the BGH terminator of VRI223 with a minimal synthetic terminator sequence derived from the rabbit /3-globin gene (Levitt et al, 1989 ) increased luciferase expression approximately two-fold (VR1223 vs. VR1255). To eliminate the possibiUty that this increase reflected the removal of BGH-derived 3' UTR sequence, a corresponding constract (VR1253) was made. In contrast to VRI223, which contains a predicted BGH-derived 3' UTR of 117 bases, both VR1253 and VR1255 contain predicted terminator-derived 3' UTR sequences of 40 bases or less, assuming the established poly (A) addition sites are utiUzed (Levitt er al, 1989; Goodwin and Rottman, 1992) . No significant difference in luciferase expression was observed between VRI 223 and VR1253, suggesting the gain in expression reaUzed with VRI255 was the sole result of the improved transcriptional termination efficiency provided by the rabbit /3-globin-derived sequences.
Expression values for the five vectors shown in Fig. 4 exhibited a skewed distribution which requked the use of a nonparametric test to determine statistical significance between plasmids ( Table 2) . A disproportionate number of low expression values {i.e., "trailing" of values toward the left bins in Fig.  4 ) was observed, consistent with the data shown in Table 2 where the median value for all tiie vectors is lower than the average value. This result indicates that a proportion of inframuscular DNA injections fails to fransfect cells efficiently. The reason for this phenomenon is currently unknown. However, it is noteworthy that the VRI255 vector, although still exhibiting a skewed distribution of expression values, had a much lower frequency of luciferase values below 64 ng/muscle compared to VR1205 ( ~ 15% v.y. >99%; Fig. 4 ). The consistentiy higher threshold of expression obtained with VR1255 vector or its derivatives suggest it should provide increased efficacy in genetic vaccination or other inframuscular DNA injection-based appUcations.
Alterations to gene regulatory elements did not appear to affect either the dose dependency or kinetics of luciferase expression. Dose-response experiments with several different plasmids demonsfrated that an increase in the inframuscular dose of DNA consistently resulted in an increase in luciferase expression. In addition, all the plasmids exhibited a peak expression plateau within the 50-to 250-/tg DNA dose range (Fig.  5A ), which differed in its average value between specific plasmids. In general, this plateau could result from Umitations in the number of plasmid DNA molecules that can enter the myonucleus (Wolff er al, 1992) , or from rate limitations inherent in cellular franscriptional or ttanslational processes. However, the former seems unUkely to account for the differences in plateau expression levels between specific plasmids. Electtophoretic analysis routinely performed in the preparation of these plasmids indicates they are predominately supercoiled (>95%) and are similar in molecular mass (ranging from 6,264 bp for nRSVLux to 8,108 bp for CMVmckLux). Therefore, assuming a delivery mechanism independent of DNA primary or secondary stiiicture, the number of copies of injected plasmid secured by myofiber nuclei is expected to be similar for each plasmid. In Ught of these assumptions, the differences in average plateau values observed between plasmids may reflect limiting concentrations of specific cellular factors goveming the rate of gene expression {e.g., ttanscription or termination factors), which are successively overcome by vector improvements, obviating the requkement for these factors. Altematively, tiiese differences in plateau values may simply reflect improvements in expression vector potency, exclusive of any Umitations imposed by cellular factors.
Analysis of luciferase expression kinetics revealed a substantial decrease in expression by 30 days postinjection. This decUne occurred for all of the plasnuds examined (Fig. 5B) , and has consistently been observed in studies with other heterologous reporter proteins, including )3-Gal, chlorampheiucol acetylttansferase, and clotting factor IX (unpubUshed observations). Possible causes of this decUne in expression include: (i) DNA degradation or exit from the nucleus; (u) naturally occurring tumover of expressing ceUs; (iu) toxic effects of accumulated ttansgene product; or (iv) promoter/enhancer shut-off mechanisms. The activity of the CMV promoter/enhancer is reported to be inhibited by interferon (Harms and SpUtter, 1995) . Thus, it is possible that cytokine secretion into the area around the ttansfected muscle, as a consequence of either locaUzed inflammatory processes or anti-reporter immune responses, down-regulates CMV promoter-based luciferase expression. However, the effect of interferon on the RSV promoter, which conferred similar luciferase expression kinetics, is unknown. Myotoxicity of accumulating ttansgene product seems unlikely to explain the temporal profile of reporter expression in ttansfected myofiber cells, because the temporal decUne in expression is similar for vectors that elicit low (e.g., nRSVLux) or high {e.g., VR1210) muscle expression.
A loss of ttansfected myofiber ceUs via a ceU-mediated immune mechanism remains a possibility. Myofiber death could result either from nonspecific immunologic mechanisms (e.g., lymphokine-activated or natural killer cells) or from specific cytotoxic T lymphocytes (CTL). The latter possibiUty may requke that ttansfected cells such as myofiber cells, macrophages, or bone marrow-derived antigen-presenting cells (Pardoll and Beckerieg, 1995) present reporter-derived peptides in the context of class I major histocompatibility (MHC) antigens. Normal myofiber cells do not express MHC antigens. However, myofiber cells can produce class I (or even class H) MHC antigens during inflammation associated with infectious diseases or in the presence of interferon gamma (Meckert et al, 1991; Hohlfeld and Engel 1994; Mantegazza and Bemasconi 1994) . With inttamuscular deUvery of plasmid DNA, muscle damage may be produced by the needle injection and/or the plasmid DNA itself may act as an inttamuscular adjuvant (Krieg et al, 1995) . Such StimuU might result in the atttaction of infilttating cells, release of cytokines such as interferon-y, and myofiber upregulation of class I MHC production. Altematively, the production of high amounts of a single inttacellular protein may perturb the myofiber enough to upregulate MHC class I production, resulting in antigen presentation, generation of specific CTL, and CTL-mediated kilUng ofthe ttansfected myofiber cell (Geissler et al, 1994) . CTL may not be successful in eliminating all of the ttansfected nuclei within the multinucleate myofiber, an occurrence that could result in the observed permanent low-level luciferase expression.
In summary, an in vivo muscle injection assay has been used to analyze the effect of systematic alterations to plasmid DNA vector elements on inttacellular reporter gene expression. The cumulative effect of alterations identified as beneficial to expression has resulted in the development of a plasmid vector (VR1255) capable of expressing up to a microgram of luciferase in a muscle after a single injection of 50 /tg of DNA. Alterations in the plasmid DNA that increased peak expression levels had no apparent effect on the dose-dependency or kinetics of expression, consistent with an enhanced inttamuscular expression potency. Additional experiments will be requked to determine whether this enhanced expression is also observed in other tissues and with other ttansgenes. However, preUminary findings indicate that expression vectors containing most of the improvements embodied by VRI 255 confer high levels of expression for human interleukin-2 (MargaUth etal, 1995; Parker et al, 1996) , canine factor IX (M. MargaUth, M. Sawdey, and M. Nolasco, unpubUshed), and murine and human erythropoietin (Svensson et al, 1996) . Plasmid DNA vectors are an inexpensive, safe, and effective delivery vehicle for gene therapy (Hom et al, 1995; Lew et al, 1995; Parker et al, 1995) . Continued optimization of these vectors should increase their utility for both genetic immunization and the systemic deUvery of therapeutic proteins.
